Literature DB >> 2966343

Identification of protease 3.4.24.11 as the major atrial natriuretic factor degrading enzyme in the rat kidney.

J L Sonnenberg1, Y Sakane, A Y Jeng, J A Koehn, J A Ansell, L P Wennogle, R D Ghai.   

Abstract

We have identified a metalloendoprotease from rat kidney cortex that cleaves the cysteine-phenylalanine bond (Cys7-Phe8) within the 17 amino acid ring structure of atrial natriuretic factor (ANF). Cleavage at this site represents the major ANF degradative activity in rat kidney, and is inhibited by the known metalloendoprotease inhibitors, thiorphan, phosphoramidon and zincov with IC50 values in the nanomolar range. Since these are specific inhibitors of protease 3.4.24.11, both protease 3.4.24.11 and ANF degrading activities were monitored during purification. Both activities copurified at each chromatographic step. Furthermore, purified protease 3.4.24.11 cleaved ANF specifically at the Cys7-Phe8 bond. It is concluded from this work that the major ANF degrading enzyme in rat kidney is protease 3.4.24.11.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2966343     DOI: 10.1016/0196-9781(88)90024-1

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  20 in total

1.  Opposite central and peripheral control by endogenous opioids of intestinal motility in fed rats.

Authors:  P J Rivière; M Liberge; D Murillo-Lopez; L Bueno
Journal:  Br J Pharmacol       Date:  1989-09       Impact factor: 8.739

2.  Differential regulation of natriuretic peptide receptors on ciliary body epithelial cells.

Authors:  R B Crook; A T Chang
Journal:  Biochem J       Date:  1997-05-15       Impact factor: 3.857

Review 3.  Natriuretic peptide metabolism, clearance and degradation.

Authors:  Lincoln R Potter
Journal:  FEBS J       Date:  2011-04-07       Impact factor: 5.542

4.  Respective roles of kallikrein and endopeptidase 24.11 in the metabolic pathway of atrial natriuretic peptide in the rat.

Authors:  Y Vanneste; S Pauwels; L Lambotte; A Michel; R Dimaline; M Deschodt-Lanckman
Journal:  Biochem J       Date:  1990-08-01       Impact factor: 3.857

5.  In vivo measurement of ANP overall turnover and identification of its main metabolic pathways under steady state conditions in humans.

Authors:  A Clerico; G Iervasi; S Berti; A Pilo; F Vitek; S Salvadori; M Marastoni; C Manfredi; M G Del Chicca; M R Iascone
Journal:  J Endocrinol Invest       Date:  1995-03       Impact factor: 4.256

6.  Characterization of neutral endopeptidase 24.11 in dog glomeruli.

Authors:  C Landry; P Santagata; W Bawab; M C Fournié-Zaluski; B P Roques; P Vinay; P Crine
Journal:  Biochem J       Date:  1993-05-01       Impact factor: 3.857

7.  A familial mutation renders atrial natriuretic Peptide resistant to proteolytic degradation.

Authors:  Deborah M Dickey; Andrea R Yoder; Lincoln R Potter
Journal:  J Biol Chem       Date:  2009-05-19       Impact factor: 5.157

8.  Pulmonary and urinary clearance of atrial natriuretic factor in acute congestive heart failure in dogs.

Authors:  M A Perrella; K B Margulies; C M Wei; L L Aarhus; D M Heublein; J C Burnett
Journal:  J Clin Invest       Date:  1991-05       Impact factor: 14.808

9.  The angiotensin II type 1 receptor-neprilysin inhibitor LCZ696 blocked aldosterone synthesis in a human adrenocortical cell line.

Authors:  Shin-Ichiro Miura; Yasunori Suematsu; Yoshino Matsuo; Sayo Tomita; Asuka Nakayama; Masaki Goto; Tadaaki Arimura; Takashi Kuwano; Eiji Yahiro; Keijiro Saku
Journal:  Hypertens Res       Date:  2016-06-23       Impact factor: 3.872

10.  Preparation of mono-radioiodinated tracers for study of the in vivo metabolism of atrial natriuretic peptide in humans.

Authors:  A Clerico; G Iervasi; C Manfredi; S Salvadori; M Marastoni; M G Del Chicca; D Giannessi; S Del Ry; M G Andreassi; L Sabatino
Journal:  Eur J Nucl Med       Date:  1995-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.